{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:25:31Z","timestamp":1787117131780,"version":"build-2736575974"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multidisciplinary tumour board (MTB) or tumour board (TB) is the \u201cgold standard\u201d for providing oncological patients\u2019 diagnosis and treatment. Often, MTBs are time-intensive, capacity-constrained, and absent or inconsistent in many routine hospitals. Despite that, in MTB, a few experienced specialists in the oncological field, sometimes the final decision is mistaken (4-47%), the necessity of treatment plan changing (12-64%), etc. Using artificial intelligence (AI) for cancer patients\u2019 treatment is a modern approach, but the main idea of our investigation should be to possibly replace MTB. On the other hand, the choice of correct treatment in oncological patients for some doctors, like surgeons, gynaecologists, and family medicine doctors, is a big trouble. They need to address the guidelines, which are so complicated quick changing. We have offered our AI algorithm, which connects doctors with patients\u2019 data, guidelines (only official sources), and then uses LLM for decision-making. Main research question \u2013 assess the role of our AI algorithm in diagnosis and treatment for cancer patients, compare with or together with MTB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, multicentre study at four specialised regional oncological hospitals. Trail period 2023-2025. Additionally, we included 37 doctors (DR) from general and rural hospitals (15 surgeons, 11 gynaecologists, 11 family medicine doctors). 728 cases in eight tumour groups were included in the study: breast 18.13% (132), colorectal 22.12% (161), lung 30.08% (219), prostate 8.79% (64), gynaecological 8.1% (59), gastric 6.59% (48), urothelial 3.99% (29), head &amp;amp; neck 2.2% (16). They were divided into 4 groups: 1) Diagnosis (D) and treatment plan (TP) with MTB only - 226 patients, 2) D and TP with AI only - 206 patients, 3) D and TP with MTB + AI - 147 patients, 4) D and TP with DR + AI - 149 patients. NCCN guidelines were used for all groups. Patients\u2019 data were ingested from the e-health system, de-identified, and normalized prior to inference. Evaluation criteria. Immediate - preparation time (PT), decision time (DT), time to recommendation (TTR), where TTR = PT + DT; Midterm - change diagnosis, change treatment plan (1 month, 6 months). We have collected MTB reports and for group N4 - questionnaires.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our proposed AI algorithm works as an intermediary between the patient, the doctor, MTB, guidelines, and LLMs. It processes data at each stage for structuring, unification, conversion, machine-readable representation, creates appropriate Python classes, and ultimately a structured supervisory layer with a decision threshold 80%. For immediate criteria we have next results (min): group 1 - PT \u2013 21.3\u00a0\u00b1\u00a03.6; DT \u2013 15.6\u00a0\u00b1\u00a06.2; TTR \u2013 36.9\u00a0\u00b1\u00a07.8; group 2 - PT \u2013 19.7\u00a0\u00b1\u00a04.1; DT \u2013 2.1\u00a0\u00b1\u00a00.02; TTR \u2013 22.4\u00a0\u00b1\u00a03.3; group 3 - PT \u2013 26.9\u00a0\u00b1\u00a04.2; DT \u2013 4.9\u00a0\u00b1\u00a00.9; TTR \u2013 29.2\u00a0\u00b1\u00a03.1; for midterm criteria (change D) results were: on 1 month \u2013 group 1 (6.79%), group 2 (5.36%), group 3 (2.78%); on 6 month \u2013 group 1 (18.22%), group 2 (19.8%), group 3 (12.4%); midterm criteria (change TP) results were: on 1 month \u2013 group 1 (11.31%), group 2 (8.78%), group 3 (4.17%); on 6 month \u2013 group 1 (25.12%), group 2 (22.84%), group 3 (15.5%); midterm criteria (change D + TP) results were: on 1 month \u2013 group 1 (13.12%), group 2 (8.78%), group 3 (4.86%); on 6 month \u2013 group 1 (28.08%), group 2 (24.3%), group 3 (14.73%). The combination of the MTB with AI gives the most effective result in reducing the change in D and TP from 28.08% to 14.73% within 6 months. For group 4, we have found next results. Before the implementation of AI, the time for TP decision in 78.4% of cases was from 30 to 60 minutes, and in 21.6% - more than 60 minutes. At 6 months, DR has time for TP decision, no more than 30 minutes in 67.7%, and among 30 and 60 minutes, 32.3%. Overall assessment using AI for TP in 3 months (good and very good) \u2013 82.8%, in 6 months \u2013 97.1%. Convenience AI in 3 months (good and very good) \u2013 54.2%, in 6 months \u2013 94.1%. Use AI after the end of the study in 3 months (good and very good) \u2013 54.3%, in 6 months \u2013 54.7%. Use in clinical practice the combination of MTB and AI, optimize TTR, decrease the percentage of change D and TP in 1,6 months, decrease the negative sides of single MTB and AI. We can use this combination for first-detected cases without comorbidities at a basic level. AI cannot replace MTB, but it empowers non-oncological clinicians and DR to generate evidence-based, auditable recommendations in settings with limited specialist capacity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The decrease in the percentage of change D and TP after MTB using AI in the first detected cases highlights the importance of conducting further studies to optimize MTB performance. The positive results of using DR assistance in the form of AI indicate the need to create other practical tools, such as an app, a pocket version, etc. To reach expert-level autonomy, further work is required: a local guideline adaptation, multimodal data ingestion, and longitudinal validation across tumour types, tumour recurrence, multiple cancers, comorbidity, and assessment of the financial efficiency of implementing AI in the work of the MTB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1785951","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:40:42Z","timestamp":1787114442000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective multi-centre evaluation of guideline\u2212based artificial intelligence to streamline multidisciplinary tumour board"],"prefix":"10.3389","volume":"16","author":[{"given":"Oleksandr","family":"Ivashchuk","sequence":"first","affiliation":[{"name":"Department of Oncology and Radiology, Bukovinian State Medical University","place":["Chernivtsi, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhiy","family":"Hovornyan","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiology, Bukovinian State Medical University","place":["Chernivtsi, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12913-020-4930-3","article-title":"The impact of tumor board on cancer care: Evidence from an umbrella review","volume":"20","author":"Specchia","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1186\/s12913-022-08112-0","article-title":"Factors influencing the quality and functioning of oncological multidisciplinary team meetings: Results of a systematic review","volume":"22","author":"Walraven","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00085","article-title":"The multidisciplinary team (MDT) approach and quality of care","volume":"10","author":"Taberna","year":"2020","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjoq-2022-002130","article-title":"Facilitators and barriers to conducting an efficient, competent and high-quality oncological multidisciplinary team meeting","volume":"12","author":"Walraven","year":"2023","journal-title":"BMJ Open Qual"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-079559","article-title":"Barriers and challenges of multidisciplinary teams in oncology management: A scoping review protocol","volume":"14","author":"Law","year":"2024","journal-title":"BMJ Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1186\/s12885-024-13188-4","article-title":"Impact of multidisciplinary team discrepancies on comparative lung cancer outcome analyses and treatment equality","volume":"24","author":"Rasmussen","year":"2024","journal-title":"BMC Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znad157","article-title":"Assessment of inter-centre agreement across multidisciplinary team meetings for patients with retroperitoneal sarcoma","volume":"110","author":"Tirotta","year":"2023","journal-title":"Br J Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164159","article-title":"The effects of multidisciplinary team meetings on clinical practice for colorectal, lung, prostate and breast cancer: A systematic review","volume":"13","author":"Ko\u010do","year":"2021","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3171\/2020.5.JNS201299","article-title":"Quantifying the utility of a multidisciplinary neuro-oncology tumor board","volume":"135","author":"Khalafallah","year":"2021","journal-title":"J Neurosurg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.885992","article-title":"Multidisciplinary team meeting proposal and final therapeutic choice in early breast cancer: Is there an agreement","volume":"12","author":"Bortot","year":"2022","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32060310","article-title":"Evaluating treatment plan modifications from surgeons\u2019 initial recommendations to multidisciplinary tumor board consensus for cancer care in a resource-limited setting","volume":"32","author":"Qureshi","year":"2025","journal-title":"Curr Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12885-020-06809-1","article-title":"Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome","volume":"20","author":"Freytag","year":"2020","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70050","article-title":"Artificial intelligence across the cancer care continuum","volume":"131","author":"Riaz","year":"2025","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01254-x","article-title":"Regulatory responses and approval status of artificial intelligence medical devices with a focus on China","volume":"7","author":"Liu","year":"2024","journal-title":"NPJ Digital Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7717\/peerj-cs.584","article-title":"Machine learning analysis of TCGA cancer data","volume":"7","author":"Li\u00f1ares-Blanco","year":"2021","journal-title":"PeerJ Comput Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473590","article-title":"Artificial intelligence and machine learning innovations to improve design and representativeness in oncology clinical trials","volume":"45","author":"Azenkot","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102498","article-title":"Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care","volume":"112","author":"Corti","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"12598","DOI":"10.1038\/s41598-020-69250-1","article-title":"Federated learning in medicine: Facilitating multi-institutional collaborations without sharing patient data","volume":"10","author":"Sheller","year":"2020","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"25676","DOI":"10.1038\/s41598-024-72894-y","article-title":"Synthetic data for privacy-preserving clinical risk prediction","volume":"14","author":"Qian","year":"2024","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1630781","article-title":"Correlation does not equal causation: The imperative of causal inference in machine learning models for immunotherapy","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpdig.2025.100231","article-title":"United States Food and Drug Administration regulation of clinical software in the era of artificial intelligence and machine learning","volume":"3","author":"Singh","year":"2025","journal-title":"Mayo Clinic Proceedings: Digital Health"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2196\/53207","article-title":"How explainable artificial intelligence can increase or decrease clinicians\u2019 trust in AI applications in health care: Systematic review","volume":"3","author":"Rosenbacke","year":"2024","journal-title":"JMIR AI"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2415898122","article-title":"The benefits and dangers of anthropomorphic conversational agents","volume":"122","author":"Peter","year":"2025","journal-title":"PNAS"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2025.100593","article-title":"397P Anthropomorphism vs. technically correct terminology in AI oncological literature: Toward a mature scientific approach","volume":"10","author":"Ivashchuk","year":"2025","journal-title":"ESMO Real World Data Digital Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100580","article-title":"Does multidisciplinary team management improve clinical outcomes in NSCLC? A systematic review with meta-analysis","volume":"4","author":"de Castro","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph192214990","article-title":"The impact of tumor boards on breast cancer care: Evidence from a systematic literature review and meta-analysis","volume":"19","author":"Di Pilla","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.46883\/2024.25921026","article-title":"Multidisciplinary team meetings: Barriers to implementation in cancer care","volume":"38","author":"He","year":"2024","journal-title":"Oncol (Williston Park)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103861","article-title":"Evaluating the impact of a tertiary multidisciplinary meeting in metastatic breast cancer: A prospective study","volume":"79","author":"Sass\u00e9","year":"2024","journal-title":"Breast"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-022-01849-y","article-title":"Implementation rate and effects of multidisciplinary team meetings on decision making about radiotherapy: An observational study at a single Japanese institution","volume":"22","author":"Ichikawa","year":"2022","journal-title":"BMC Med Inf Decis Making"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2024.1710","article-title":"Optimising head and neck cancer patient management: The crucial contributions of multidisciplinary tumour board decision-making","volume":"18","author":"Ayub","year":"2024","journal-title":"ecancermedicalscience"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1205224","article-title":"Changes in multidisciplinary team decisions in a high volume head and neck oncological center following those made in its preferred partner","volume":"13","author":"Hendrickx","year":"2023","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3210","article-title":"Guidelines for clinical trial protocols for interventions involving artificial intelligence: The SPIRIT-AI extension","volume":"370","author":"Rivera","year":"2020","journal-title":"BMJ"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01772-9","article-title":"Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI","volume":"28","year":"2022","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01312-x","article-title":"How medical AI devices are evaluated: Limitations and recommendations from an analysis of Food and Drug Administration approvals","volume":"27","author":"Wu","year":"2021","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jclinepi.2021.06.024","article-title":"Reporting of prognostic clinical prediction models based on machine learning methods in oncology needs to be improved","volume":"138","author":"Dhiman","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s41512-022-00126-w","article-title":"Risk of bias of prognostic models developed using machine learning: A systematic review in oncology","volume":"6","author":"Dhiman","year":"2022","journal-title":"Diagn Progn Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01113","article-title":"A process framework for ethically deploying artificial intelligence in oncology","volume":"40","author":"Hantel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.4077","article-title":"Perspectives of oncologists on the ethical implications of using artificial intelligence for cancer care","volume":"7","author":"Hantel","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(20)30292-2","article-title":"Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015\u201320): A comparative analysis","volume":"3","author":"Muehlematter","year":"2021","journal-title":"Lancet Digital Health"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2104626","article-title":"The clinician and dataset shift in artificial intelligence","volume":"385","author":"Finlayson","year":"2021","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35307","article-title":"Uses and limitations of artificial intelligence for oncology","volume":"130","author":"Kolla","year":"2024","journal-title":"Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/AIra2401164","article-title":"The use of artificial intelligence for cancer therapeutic decision-making","volume":"2","author":"Elemento","year":"2025","journal-title":"NEJM AI"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/CCI-25-00123","article-title":"Safe and responsible use of artificial intelligence in health care: Current regulatory landscape and considerations for regulatory policy","volume":"9","author":"Shah","year":"2025","journal-title":"JCO Clin Cancer Inf"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-01794-w","article-title":"Responsible Artificial Intelligence governance in oncology","volume":"8","author":"Stetson","year":"2025","journal-title":"NPJ Digital Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3164","article-title":"Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: The CONSORT-AI extension","volume":"370","author":"Liu","year":"2020","journal-title":"BMJ"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1785951\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:40:47Z","timestamp":1787114447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1785951\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":47,"alternative-id":["10.3389\/fonc.2026.1785951"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1785951","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1785951"}}